PDCD1 and neoplasm: Thereby, this leads to the re-expression of PD-L1 in tumor cells, the augment and/or activation of TILs when combined with the PD-1/PD-L1 blockade, and the concomitant conversion of a cold tumor immune microenvironment to a hot state.